COMPANY PROFILE Contact details


900 Ridgebury Rd PO Box 368 Ridgefield CT 06877 USA


Tel.: +1 800 243 0127 BOEHRINGER INGELHEIM


www.us.boehringer-ingel- heim.com


Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest US subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.


The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.


Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.


In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.


For more information please visit www.us.boehringer-ingelheim.com Contact details


Uppsala Science Park Dag Hammarskjölds väg 54


SE-751 83 Uppsala Sweden


GYROS


information@gyros.com Tel.: +46 18 56 63 00 www.gyros.com


Gyros’ immunoassay platforms bring increased productivity and efficiency to the development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize Gyros’ platforms to boost time-critical workflows and to meet increasingly stringent regulatory demands on testing. Spanning the entire spectrum of immunoassays, the platforms accelerate assay development, minimize sample and reagent consumption, and cut the time to result. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.


Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. Gyros’ immunoassay platforms bring increased productivity and efficiency to the development of biotherapeutics and vaccines. Major biopharmaceutical companies and their service providers utilize Gyros’ platforms to boost time- critical workflows and to meet increasingly stringent regulatory demands on testing. Spanning the entire spectrum of immunoassays, the platforms cut the time to result significantly. Faster assay development times, and unattended running of assays at nanoliter-scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry. The company has around 70 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, plus a growing network of distributors.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154